Effect of prehydration solution on hearing threshold after chemotherapy in patients with head and neck cancers: a retrospective study
1
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background: The study aimed to evaluate the effect of prehydration solution on hearing thresholds after cisplatin chemotherapy. Methods: In this retrospective cohort study, we reviewed the data of patients who underwent ≥3 courses of cisplatin-based chemotherapy for locally advanced head and neck cancers at a tertiary referral center (n=64). The dextrose solution (DW) group (n=26) received 2 L of normal saline and 1 L of 5% dextrose. The Hartmann solution (HS) group (n=38) received 2 L of normal saline and 1 L of HS. Hearing data were measured 1 day before starting the first course of chemotherapy, and again 20 days after the first, second, and third courses of chemotherapy. The severity of hearing loss was evaluated using the Common Terminology Criteria for Adverse Events (CTCAE). Results: Thresholds at all frequencies after chemotherapy were greater in the DW group than in the HS group. The increase in thresholds in 1 to 4 kHz after the third course of chemotherapy was greater in the DW group than in the HS group. CTCAE grades after the second and third courses of chemotherapy were greater in the DW group than in the HS group. Logistic regression showed that the odds ratio for CTCAE grade 3 or 4 after the third course of chemotherapy in the DW group was 4.84 on univariate analysis. Conclusion: Prehydration using a solution with salt was associated with a decrease in change in hearing thresholds after cisplatin chemotherapy in patients with head and neck cancers.
Abstract
Background: The study aimed to evaluate the effect of prehydration solution on hearing thresholds after cisplatin chemotherapy. Methods: In this retrospective cohort study, we reviewed the data of patients who underwent ≥3 courses of cisplatin-based chemotherapy for locally advanced head and neck cancers at a tertiary referral center (n=64). The dextrose solution (DW) group (n=26) received 2 L of normal saline and 1 L of 5% dextrose. The Hartmann solution (HS) group (n=38) received 2 L of normal saline and 1 L of HS. Hearing data were measured 1 day before starting the first course of chemotherapy, and again 20 days after the first, second, and third courses of chemotherapy. The severity of hearing loss was evaluated using the Common Terminology Criteria for Adverse Events (CTCAE). Results: Thresholds at all frequencies after chemotherapy were greater in the DW group than in the HS group. The increase in thresholds in 1 to 4 kHz after the third course of chemotherapy was greater in the DW group than in the HS group. CTCAE grades after the second and third courses of chemotherapy were greater in the DW group than in the HS group. Logistic regression showed that the odds ratio for CTCAE grade 3 or 4 after the third course of chemotherapy in the DW group was 4.84 on univariate analysis. Conclusion: Prehydration using a solution with salt was associated with a decrease in change in hearing thresholds after cisplatin chemotherapy in patients with head and neck cancers.
참고문헌 (21)
- Rosenberg B, "Inhibition of cell division in Escherichia coli by electrolysis products from a platinum electrode", Nature, 205, pp.698~699 (1965)
- Laurell G, "Dose-dependent inner ear changes after i. v. administration of cisplatin", J Otolaryngol, 20, pp.158~167 (1991)
- Wu X, "Allicin protects auditory hair cells and spiral ganglion neurons from cisplatin-induced apoptosis", Neuropharmacology, 116, pp.429~440 (2017)
- Breglio AM, "Cisplatin is retained in the cochlea indefinitely following chemotherapy", Nat Commun, 8, pp.1654~ (2017)
- Santos NA, "Overview of cisplatin-induced neurotoxicity and ototoxicity, and the protective agents", Food Chem Toxicol, 136, pp.111079~ (2020)
- Horie S, "Guidelines for treatment of renal injury during cancer chemotherapy 2016", Clin Exp Nephrol, 22, pp.210~244 (2018)
- Earhart RH, "Improvement in the therapeutic index of cisplatin(NSC 119875)by pharmacologically induced chloruresis in the rat", Cancer Res, 43, pp.1187~1194 (1983)
- Daley-Yates PT, "A study of the protective effect of chloride salts on cisplatin nephrotoxicity", Biochem Pharmacol, 34, pp.2363~2369 (1985)
- Ahn D, "Phase II trial of individualized", dynamic cisplatin regimens for definitive concurrent chemoradiation therapy in patients with head and neck squamous cell carcinoma, 2020, pp.9, 9256~9265
- "Common Terminology Criteria for Adverse Events (CTCAE v5.0)" (2017)[URL]
- Trendowski MR, "Genetic and modifiable risk factors contributing to cisplatin-induced toxicities", Clin Cancer Res, 25, pp.1147~1155 (2019)
- More SS, "Role of the copper transporter, CTR1, in platinum-induced ototoxicity", J Neurosci, 30, pp.9500~9509 (2010)
- Ciarimboli G, "Membrane transporters as mediators of cisplatin side-effects", Anticancer Res, 34, pp.547~550 (2014)
- Karasawa T, "An integrated view of cisplatin-induced nephrotoxicity and ototoxicity", Toxicol Lett, 237, pp.219~227 (2015)
- Duval M, "Meta-analysis of the efficacy of amifostine in the prevention of cisplatin ototoxicity", J Otolaryngol Head Neck Surg, 41, pp.309~315 (2012)
- Freyer DR, "Prevention of cisplatin-induced ototoxicity in children and adolescents with cancer : a clinical practice guideline", Lancet Child Adolesc Health, 4, pp.141~150 (2020)
- Paken J, "Cisplatin-associated ototoxicity : a review for the health professional", J Toxicol, 2016, pp.1809394~ (2016)
- Paken J, "A review of cisplatin-associated ototoxicity", Semin Hear, 40, pp.108~121 (2019)
- Santoso JT, "Saline, mannitol, and furosemide hydration in acute cisplatin nephrotoxicity : a randomized trial", Cancer Chemother Pharmacol, 52, pp.13~18 (2003)
- Tang Q, "Cisplatin-induced ototoxicity : updates on molecular mechanisms and otoprotective strategies", Eur J Pharm Biopharm, 163, pp.60~71 (2021)
- Rabik CA, "Molecular mechanisms of resistance and toxicity associated with platinating agents", Cancer Treat Rev, 33, pp.9~23 (2007)